Trimel Receives FDA Approval for Natesto™ Nasal Gel to Treat Men with Low Testosterone Canada NewsWire TORONTO, May 28, 2014 Natesto™ is the first nasal testosterone replacement therapy approved by FDA TORONTO , May 28, 2014 /CNW/ – Trimel Pharmaceuticals Corporation (TSX: TRL) announced today that the United States Food and Drug Administration (FDA) has approved Natesto™ (testosterone), formerly CompleoTRT™, the first and only testosterone nasal gel for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone. Natesto™ is self-administered via a nasal applicator thereby minimizing the risk of secondary exposure to testosterone of women or children. “In my practice I regularly encounter men demonstrating symptoms of hypogonadism and physicians will increasingly see this as the North American population ages,” said Dr. […]